Buy & Sell Corning Incorporated (GLW) – Corning Incorporated Price Today
Key Stats
- $149.70BMarket Cap
- TechnologySector
- -16.52%3M Drawdown
- $157.87BEnterprise Value
- 0.64%Dividend Yield
- 59% Buy | 41% SellTrading Activity
- 27 daysTypical Hold Time
Corning Incorporated (GLW) is currently valued at a market capitalization of $149.70B, with an enterprise value of $157.87B. Over the past 52 weeks, Corning Incorporated has traded between a low of $49.6 and a high of $208.36, highlighting its annual price range. Over the past three months, Corning Incorporated has recorded a drawdown of -16.52%, reflecting recent price volatility. Corning Incorporated offers a dividend yield of 0.64%, with the most recent dividend of $0.28 paid on 29 May 26. On average, investors hold Corning Incorporated for approximately 27 days, indicating typical investor behavior on the platform.
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Most Recent News
ConocoPhillips director sells shares amid oil price drop and rising supply concerns
A director at ConocoPhillips sold 1,974 shares worth about $235,000 following a 2.2% drop in the company's stock price amid a broader oil market downturn. The decline in oil prices was driven by increasing global supply, with key indicators like Bren...
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...
Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
